Efficiency of hemosorption in treatment of patients with ulcerative colitis.
One hundred and seven sessions of hemosorption were performed on 77 patients with severe ulcerative colitis. Clinically, improvement was demonstrated in the reduction of the signs of intoxication in 50 to 60 per cent of patients. Combination of hemosorption and anti-inflammatory medication allowed to achieve a remission or a marked improvement determined by clinical observation or endoscopy of 39 from 52 patients with a severe, total form of the disease, whereas toxic influence of sulfasalazine was controlled and extra-intestinal complications were weakened in 8 patients from 11. Thirteen patients were operated upon due to inefficiency of therapy. Hemosorption contributed to reduction of content of protein molecules with mean molecular weight (61 per cent), phenol (73 per cent), and endotoxin of gram-negative bacteria (50 per cent). Dynamics of acute phase reactants and humoral immune factors testifies to a weak anti-inflammatory action of hemosorption. Reduced levels of plasma protein, albumin, potassium and cholesterol were corrected or spontaneously returned to normal.
D000936:Antigen-Antibody Complex / Q000302:isolation & purification; D003093:Colitis, Ulcerative / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006464:Hemoperfusion; D006801:Humans; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use; D014118:Toxins, Biological / Q000097:blood / Q000302:isolation & purification
D000936:Antigen-Antibody Complex; D014118:Toxins, Biological; D012460:Sulfasalazine